Victoza 3-Pak (Liraglutide) — Medicare Part D spending
Novo Nordisk · Rank #51 by total Part D spend · CMS data year 2023
Medicare Part D spent $1,004,635,145 on Victoza 3-Pak (Liraglutide) in 2023, the #51 drug by total Part D spending out of 3,598 drugs. That worked out to about $126.95 per dosage unit, $1,750 per claim and $7,064 per beneficiary, across 574,218 claims for 142,213 beneficiaries. Average spending per dosage unit rose +4.5% from 2022. These are aggregate Medicare program figures (gross drug cost), not the price you pay.
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
Victoza 3-Pak (Liraglutide) spending at a glance (2023)
| Metric | Victoza 3-Pak (Liraglutide) |
|---|---|
| Total Part D spending (2023) | $1,004,635,145 |
| Total spending (2022) | $1,238,594,872 |
| Year-over-year change in total spending | -18.9% |
| Average spending per dosage unit (2023) | $126.95 |
| Change in spend per dosage unit (YoY) | +4.5% |
| Avg annual change per dosage unit (2019-2023 CAGR) | +5.5% |
| Average spending per claim (2023) | $1,750 |
| Average spending per beneficiary (2023) | $7,064 |
| Total claims (2023) | 574,218 |
| Beneficiaries (2023) | 142,213 |
| Total dosage units (2023) | 7,913,341 |
| Manufacturer(s) | Novo Nordisk |
| National rank by total spend (of 3,598 drugs) | #51 |
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
2022 vs 2023
| Metric | 2022 | 2023 | Change |
|---|---|---|---|
| Total spending | $1,238,594,872 | $1,004,635,145 | -18.9% |
| Avg spend per dosage unit | $121.54 | $126.95 | +4.5% |
| Avg spend per claim | $1,711 | $1,750 | — |
| Avg spend per beneficiary | $7,409 | $7,064 | — |
| Total claims | 724,049 | 574,218 | — |
| Beneficiaries | 167,181 | 142,213 | — |
How Victoza 3-Pak compares with nearby drugs
Drugs with total Part D spending closest to Victoza 3-Pak (Liraglutide):
| Drug (rank) | Total spend 2023 | Per dosage unit | Per-unit YoY |
|---|---|---|---|
| Victoza 3-Pak (Liraglutide) (this drug, #51) | $1,004,635,145 | $126.95 | +4.5% |
| Levemir Flexpen (Insulin Detemir) (#49) | $1,025,556,477 | $32.59 | — |
| Opsumit (Macitentan) (#50) | $1,018,837,123 | $424.66 | +8.3% |
| Atorvastatin Calcium (#52) | $1,000,689,622 | $0.21 | +10.6% |
| Rinvoq (Upadacitinib) (#53) | $976,330,771 | $219.05 | +10.1% |
| Vraylar (Cariprazine HCl) (#54) | $935,653,082 | $48.81 | +5.8% |
Frequently asked questions
How much does Medicare Part D spend on Victoza 3-Pak?
Medicare Part D spent $1,004,635,145 on Victoza 3-Pak (Liraglutide) in 2023 (the latest CMS data year), across 574,218 claims for 142,213 beneficiaries. That ranks #51 of 3,598 drugs by total Part D spending. This is gross drug cost (Medicare, plan and beneficiary payments combined), not the price you personally pay.
What is the average spending per dosage unit for Victoza 3-Pak?
In 2023, the weighted average Medicare Part D spending per dosage unit for Victoza 3-Pak (Liraglutide) was $126.95. Compared with 2022 it rose +4.5%. A "dosage unit" is one pill, tablet, milliliter or other billing unit, so this is not the price of a prescription.
Who makes Victoza 3-Pak?
CMS attributes Victoza 3-Pak (Liraglutide) to Novo Nordisk in the 2023 Part D spending file. Average spending per claim was $1,750 and per beneficiary $7,064.
Is the Victoza 3-Pak figure the price I pay?
No. These are aggregate Medicare Part D program figures (total gross drug cost and averages across all claims), published by CMS for transparency. Your out-of-pocket cost depends on your plan, formulary, deductible and coverage phase. Always check your plan and talk to your pharmacist or doctor.
Keep exploring
Source & what this means
Figures are from the CMS Medicare Part D Spending by Drug dataset (data year 2023, US public domain). "Total spending" is the gross drug cost — Medicare, plan and beneficiary payments combined — for Part D claims; it is not a list price, a negotiated price, or what any individual pays. Spending per dosage unit is volume-weighted across formulations. This is general public-spending information, not medical or pricing advice. Your own cost depends on your plan, deductible and coverage phase — verify with your Part D plan and a pharmacist. Data as of June 2026. See our methodology and disclaimer.
Last updated: 2026-06-20